Full Press Release Details
Lexaria Maintains OTCQB Marketplace Status
Kelowna, BC / February 2, 2015 / Lexaria, Corp. (OTCQB:LXRP)
(CSE:LXX) (the Company ) announces the Company has
submitted all the mandatory documents and has successfully met all of the
requirements for continued listing and trading on the OTCQB Marketplace. Partly
as a result of this, Realtime Level II Quote Display Service is now available to
investors free at www.otcmarkets.com/stock/LXRP/quote
Lexaria is a US Company that trades in the USA on the OTCQB
venture stage marketplace for early stage and developing U.S. and international
companies. Companies listed at OTCQB are current in their reporting and undergo
an annual verification and management certification process. Lexaria has
continuously filed its quarterly and annual reports, and more, at the SEC
EDGAR site since 2006.
Since 2009, Lexaria also has traded on the Canadian Securities
Exchange in Canada, the fastest growing stock exchange in North America. Lexaria
is eligible for registered retirement accounts for Canadian investors, is
compliant with all CSE regulatory policies, and is Fully Reporting under
Canadian securities laws.
Lexaria is pleased to continue its open and transparent
communications and accessibility with its investors across North America and
expects this tradition to continue in 2015 and beyond.
Lexaria's shares are quoted in the USA with
symbol LXRP and in Canada with symbol LXX. The company searches for projects
that could provide potential above-market returns. www.lexarienergy.com
legal CBD oil extracts, grown from legal hemp in locations where it is legal to
do so, in ViPovaTM-branded tea. ViPovaTM uses its
patent-pending process to infuse concentrated amounts of CBD within lipids in
its tea, providing more bioactivity and comfort to the body during the
absorption process. Only ViPovaTM has this ground-breaking technology
for CBD/lipid infusion. www.vipova.com
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. Such forward-looking statements are
estimates reflecting the Company's best judgment based upon current information
and involve a number of risks and uncertainties, and there can be no assurance
that other factors will not affect the accuracy of such forward-looking
statements. Access to capital, or lack thereof, is a major risk and there is no
assurance that the Company will be able to raise required working capital.
Current oil and gas production rates may not be sustainable and targeted
production rates may not occur. Factors which could cause actual results to
differ materially from those estimated by the Company include, but are not
limited to, government regulation, managing and maintaining growth, the effect
of adverse publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements and filings.
There is no assurance that the medical marijuana, CBD sector, or alternative
health businesses will provide any benefit to Lexaria, or that the Company will
experience any growth through participation in these sectors. There is no
assurance that existing capital is sufficient for the Company's needs or that it
will need to attempt to raise additional capital. There is no assurance that any
cannabinoid-based product will promote, assist, or maintain any beneficial human
health conditions whatsoever. No statement herein has been evaluated by the Food
and Drug Administration (FDA). ViPovaTM products are not intended to
diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.